EARLY AND LATE RESPONSE ASSESSMENT WITH FDG-PET AFTER BEACOPP-BASED CHEMOTHERAPY IN ADVANCED-STAGE HODGKIN LYMPHOMA PATIENTS HAS A HIGH NEGATIVE PREDICTIVE VALUE

被引：0
|
作者：
Markova, J. [1 ]
Kobe, C. [2 ]
Skopalova, M. [3 ]
Zikavska, L. [1 ]
Vernerova, Z. [1 ]
Klaskova, K. [1 ]
Dedeckova, K. [4 ]
Eich, H. T. [5 ]
Dietlein, M. [2 ]
Fuchs, M. [6 ]
Engert, A. [7 ]
Kozak, T. [1 ]
机构：
[1] Univ Hosp Kralovske Vinohrady, Prague 0, Czech Republic
[2] Univ Cologne, Dept Nucl Med, D-50924 Cologne, Germany
[3] Na Homolce Hosp, PET Ctr, Dept Nucl Med, Prague, Czech Republic
[4] Univ Hosp Na Bulovce, Inst Radiat Oncol, Prague 8, Czech Republic
[5] Univ Cologne, Dept Radiat Oncol, D-50924 Cologne, Germany
[6] Univ Cologne, German Hodgkin Study Grp, D-50924 Cologne, Germany
[7] Univ Cologne, Dept Internal Med 1, D-50924 Cologne, Germany
来源：
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL | 2009年 / 94卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
0084
引用
收藏
页码：33 / 33
页数：1
相关论文
共 50 条
  • [41] Early interim negative FDG-PET/CT is a high predictive factor for progression-free survival in Hodgkin lymphoma.
    Dann, Eldad J.
    Bar-Shalom, Rachel
    Tamir, Ada
    Haim, Nissim
    Avivi, Irit
    Gaitini, Diana
    Ben-Shachar, Menachem
    Israel, Ora
    Rowe, Jacob M.
    Epelbaum, Ron
    BLOOD, 2006, 108 (11) : 227B - 227B
  • [42] EARLY INTERIM FDG-PET IN ADVANCED-STAGE HODGKIN LYMPHOMA (HL). LONG-TERM RESULTS OF THE ITALIAN-DANISH COOPERATIVE STUDY
    Gallamini, A.
    Hutchings, M.
    Rigacci, L.
    Specht, L.
    Merli, F.
    Hansen, M.
    Patti, C.
    Loft, A.
    Di Raimondo, F.
    D'Amore, F.
    Biggi, A.
    Pregno, P.
    Stelitano, C.
    Sancetta, R.
    Trentin, L.
    Luminari, S.
    Iannitto, E.
    Viviani, S.
    Pierri, I.
    Torchio, P.
    Levis, A.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2008, 93 : 191 - 191
  • [43] High negative predictive value of FDG-PET for assessment of progressive disease in patients with soft tissue sarcoma.
    Gauthier, H
    Levy, E
    Merlet, P
    Thirion, P
    Syrota, A
    Meignan, M
    JOURNAL OF NUCLEAR MEDICINE, 1999, 40 (05) : 259P - 259P
  • [44] Radiation therapy dose consideration in Hodgkin Lymphoma after chemotherapy: implication of metabolic response assessment in 18 FDG-PET/CT
    Molina, M. A.
    Sardi, M.
    Colombo, M. S.
    Diaz, F.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2018, 45 : S489 - S489
  • [45] EARLY CHEMOTHERAPY INTENSIFICATION WITH BEACOPP IN HIGH-RISK, INTERIM-PET POSITIVE ADVANCED-STAGE HODGKIN LYMPHOMA, IMPROVES THE OVERALL TREATMENT OUTCOME OF ABVD: A GITIL MULTICENTER CLINICAL STUDY
    Gallamini, A.
    Fiore, F.
    Sorasio, R.
    Rambaldi, A.
    Patti, C.
    Stelitano, C.
    Viviani, S.
    Di Raimondo, F.
    Feldman, T.
    Biggi, A.
    Rossi, A.
    Mistretta, A.
    Bonfante, V.
    Chiarenza, A.
    Cantonetti, M.
    Gavarotti, P.
    Tarella, C.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2009, 94 : 204 - 204
  • [46] Treatment Reduction in Patients with Advanced-Stage Hodgkin Lymphoma and Negative Interim FDG-PET: Final Results of the International, Randomized, Phase 3 HD18 Trial by the German Hodgkin Study Group
    Kobe, C.
    Goergen, H.
    Fuchs, M.
    Eich, H. T.
    Baues, C.
    Diehl, V.
    Kuhnert, G.
    Drzezga, A.
    Dietlein, M.
    Engert, A.
    Borchmann, P.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2017, 44 : S312 - S312
  • [47] Combined escBEACOPP-ABVD therapy for advanced Hodgkin's lymphoma patients with high ips score: An effective regimen and low positive predictive value of early FDG-PET/CT
    Aviador, A.
    Bulvik, S.
    Dann, E.
    Levi, I.
    Perez-Avraham, G.
    Shemtov, N.
    Shimoni, A.
    Nagler, A.
    Ben-Bassat, I.
    Polliack, A.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2007, 92 : 66 - 66
  • [48] The prognostic value of the tumor/microenvironment signature compared to early pet scan in advanced-stage, ABVD-treated Hodgkin lymphoma patients
    Gallamini, A.
    Agostinelli, C.
    Rigacci, L.
    D'Amore, F.
    Merli, F.
    Zinzani, P.
    Vitolo, U.
    Patti, C.
    Stelitano, C.
    Di Raimondo, F.
    Levis, A.
    Trentin, L.
    Chisesi, T.
    Kamper, P.
    Pileri, S.
    ANNALS OF ONCOLOGY, 2008, 19 : 125 - 125
  • [49] Does interim 18F-FDG-PET response-adapted therapy really benefit advanced-stage Hodgkin lymphoma patients?
    Adams, Hugo J. A.
    Kwee, Thomas C.
    NUCLEAR MEDICINE COMMUNICATIONS, 2016, 37 (12) : 1333 - 1334
  • [50] The value of dual point interim FDG-PET/CT assessment in a patient with advanced Hodgkin's lymphoma (HL) with bulky masses treated with ABVD chemotherapy
    Zaucha, J.
    Malkowski, B.
    Gallamini, A.
    CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2012, 82 : S27 - S28
12345